(SGRY) Surgery Partners - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US86881A1007
SGRY: Surgical, Diagnostic, Ancillary, Medical, Healthcare
Surgery Partners Inc. (NASDAQ: SGRY) stands as a prominent figure in the ambulatory surgery sector, operating an extensive network of surgical facilities across the United States. Their focus on non-emergency procedures ensures a stable demand, underpinned by specialties like orthopedics and pain management, which are areas of consistent patient need.
Beyond their surgical services, the company diversifies its revenue streams through a range of ancillary offerings, including diagnostic imaging and physical therapy. This diversification not only enhances operational resilience but also positions the company to capitalize on multiple healthcare segments.
With a market capitalization of $3.24 billion, Surgery Partners presents a forward P/E ratio of 24.51, indicating expectations for growth. Their financial metrics suggest a company well-positioned in the healthcare facilities sector, leveraging scale and a broad service portfolio to maintain competitiveness and drive potential expansion.
Additional Sources for SGRY Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
SGRY Stock Overview
| Market Cap in USD | 2,913m |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| GiC Sub-Industry | Health Care Facilities |
| IPO / Inception | 2015-10-01 |
SGRY Stock Ratings
| Growth 5y | 19.7% |
| Fundamental | 6.96% |
| Dividend | 0.0% |
| Rel. Strength | -21.7 |
| Analysts | 4.38/5 |
| Fair Price Momentum | 17.92 USD |
| Fair Price DCF | 37.97 USD |
SGRY Dividends
No Dividends PaidSGRY Growth Ratios
| Growth Correlation 3m | 10.3% |
| Growth Correlation 12m | -35.3% |
| Growth Correlation 5y | -12.8% |
| CAGR 5y | 22.16% |
| CAGR/Max DD 5y | 0.31 |
| Sharpe Ratio 12m | -1.88 |
| Alpha | -13.55 |
| Beta | 2.735 |
| Volatility | 37.04% |
| Current Volume | 1689.1k |
| Average Volume 20d | 829.2k |
As of April 08, 2025, the stock is trading at USD 20.51 with a total of 1,689,105 shares traded.
Over the past week, the price has changed by -13.64%, over one month by -14.72%, over three months by -0.63% and over the past year by -25.01%.
Neither. Based on ValueRay Fundamental Analyses, Surgery Partners is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 6.96 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SGRY as of April 2025 is 17.92. This means that SGRY is currently overvalued and has a potential downside of -12.63%.
Surgery Partners has received a consensus analysts rating of 4.38. Therefor, it is recommend to buy SGRY.
- Strong Buy: 8
- Buy: 2
- Hold: 3
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, SGRY Surgery Partners will be worth about 19.7 in April 2026. The stock is currently trading at 20.51. This means that the stock has a potential downside of -3.85%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 31.9 | 55.6% |
| Analysts Target Price | 33.5 | 63.4% |
| ValueRay Target Price | 19.7 | -3.9% |